U
Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.000.00%
D
Sell
8/26/2019Upgraded
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D from D- on 8/26/2019 due to an increase in the volatility index, total return index and valuation index.
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D from D- on 8/26/2019 due to an increase in the volatility index, total return index and valuation index.
D
Sell
12/11/2018Downgrade
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D- from D on 12/11/2018 due to a decline in the volatility index and total return index.
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D- from D on 12/11/2018 due to a decline in the volatility index and total return index.
D
Sell
11/26/2018Upgraded
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D from D- on 11/26/2018 due to a large increase in the growth index, efficiency index and volatility index. Operating cash flow increased 19.11% from -$1.02M to -$821, total revenue increased 5.23% from $2.28M to $2.39M, and total capital increased 4.14% from $11.99M to $12.49M.
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D from D- on 11/26/2018 due to a large increase in the growth index, efficiency index and volatility index. Operating cash flow increased 19.11% from -$1.02M to -$821, total revenue increased 5.23% from $2.28M to $2.39M, and total capital increased 4.14% from $11.99M to $12.49M.
D
Sell
6/5/2018Upgraded
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D- from E+ on 6/5/2018 due to an increase in the volatility index and total return index.
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D- from E+ on 6/5/2018 due to an increase in the volatility index and total return index.
E
Sell
5/18/2018Downgrade
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to E+ from D- on 5/18/2018 due to a noticeable decline in the growth index, efficiency index and total return index. Operating cash flow declined 270.19% from -$463 to -$1.71M, EBIT declined 115.93% from -$1.41M to -$3.05M, and net income declined 63.61% from -$1.61M to -$2.63M.
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to E+ from D- on 5/18/2018 due to a noticeable decline in the growth index, efficiency index and total return index. Operating cash flow declined 270.19% from -$463 to -$1.71M, EBIT declined 115.93% from -$1.41M to -$3.05M, and net income declined 63.61% from -$1.61M to -$2.63M.
D
Sell
1/19/2018Downgrade
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D- from D on 1/19/2018 due to a decline in the volatility index and total return index.
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D- from D on 1/19/2018 due to a decline in the volatility index and total return index.
D
Sell
11/16/2017Upgraded
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D from D- on 11/16/2017 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 38.02% from -$747 to -$463, total revenue increased 32.03% from $1.28M to $1.69M, and earnings per share increased from -$0.0637 to -$0.06.
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D from D- on 11/16/2017 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 38.02% from -$747 to -$463, total revenue increased 32.03% from $1.28M to $1.69M, and earnings per share increased from -$0.0637 to -$0.06.
D
Sell
8/1/2017Downgrade
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D- from D on 8/1/2017 due to a substantial decline in the total return index, volatility index and growth index. Operating cash flow declined 1,416.33% from $49 to -$645, and total revenue declined 3.12% from $1.95M to $1.89M.
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D- from D on 8/1/2017 due to a substantial decline in the total return index, volatility index and growth index. Operating cash flow declined 1,416.33% from $49 to -$645, and total revenue declined 3.12% from $1.95M to $1.89M.
D
Sell
11/17/2016Downgrade
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D from D+ on 11/17/2016 due to a significant decline in the growth index, solvency index and efficiency index. Operating cash flow declined 117.49% from -$183 to -$398, EBIT declined 80.67% from -$119 to -$215, and net income declined 51.49% from -$202 to -$306.
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D from D+ on 11/17/2016 due to a significant decline in the growth index, solvency index and efficiency index. Operating cash flow declined 117.49% from -$183 to -$398, EBIT declined 80.67% from -$119 to -$215, and net income declined 51.49% from -$202 to -$306.
D
Sell
5/13/2016Upgraded
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D+ from D on 5/13/2016 due to a substantial increase in the growth index and total return index. Earnings per share increased from -$0.0291 to $0, and EBIT increased 35.3% from -$541 to -$350.
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to D+ from D on 5/13/2016 due to a substantial increase in the growth index and total return index. Earnings per share increased from -$0.0291 to $0, and EBIT increased 35.3% from -$541 to -$350.
D
Sell
3/11/2016Downgrade
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D from C- on 3/11/2016 due to a significant decline in the volatility index and total return index.
C
Hold
1/15/2016Downgrade
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to C- from C on 1/15/2016 due to a large decline in the total return index and volatility index.
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to C- from C on 1/15/2016 due to a large decline in the total return index and volatility index.
C
Hold
12/31/2015Upgraded
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to C from C- on 12/31/2015 due to a noticeable increase in the total return index, valuation index and efficiency index. Total capital increased 3.47% from $12.29M to $12.72M.
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to C from C- on 12/31/2015 due to a noticeable increase in the total return index, valuation index and efficiency index. Total capital increased 3.47% from $12.29M to $12.72M.
C
Hold
7/10/2015Upgraded
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to C- from D+ on 7/10/2015 due to an increase in the total return index.
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to C- from D+ on 7/10/2015 due to an increase in the total return index.
D
Sell
6/15/2015Downgrade
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D+ from C- on 6/15/2015 due to a decline in the total return index, growth index and valuation index.
Medite Cancer Diagnostics, Inc. (MDIT) was downgraded to D+ from C- on 6/15/2015 due to a decline in the total return index, growth index and valuation index.
C
Hold
5/27/2015Upgraded
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to C- from D+ on 5/27/2015 due to a large increase in the growth index and solvency index. The quick ratio increased from 0.33 to 0.38, and debt to equity declined from 0.54 to 0.47.
Medite Cancer Diagnostics, Inc. (MDIT) was upgraded to C- from D+ on 5/27/2015 due to a large increase in the growth index and solvency index. The quick ratio increased from 0.33 to 0.38, and debt to equity declined from 0.54 to 0.47.
D
Sell
5/8/2015Upgraded
Medite Cancer Diagnostics, Inc. (MDITE) was upgraded to D+ from D on 5/8/2015 due to a substantial increase in the volatility index and total return index.
Medite Cancer Diagnostics, Inc. (MDITE) was upgraded to D+ from D on 5/8/2015 due to a substantial increase in the volatility index and total return index.
D
Sell
8/29/2014Downgrade
CytoCore, Inc. (CYOE) was downgraded to D from C on 8/29/2014 due to a significant decline in the volatility index, efficiency index and growth index. Net income declined 122.83% from $219 to -$50, and EBIT declined 68.65% from $370 to $116.
CytoCore, Inc. (CYOE) was downgraded to D from C on 8/29/2014 due to a significant decline in the volatility index, efficiency index and growth index. Net income declined 122.83% from $219 to -$50, and EBIT declined 68.65% from $370 to $116.
OTC PK
12/17/2024 1:17PM Eastern
Quotes delayed
